Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with apatinib for unresectable colorectal liver metastases
ChiCTR-OPN-17013220Phase 4Recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoint: time to progression. Started Nov 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on ChiCTR-OPN-17013220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17013220.